Bozena Michniak-Kohn

Dr. Bozena Michniak-Kohn

Ernest Mario School of Pharmacy; Center for Dermal Research (CDR) & Laboratory for Drug Delivery (LDD), NJ Center for Biomaterials, Life Sciences Building, Rutgers-The State University of New Jersey, 145, Bevier Road, Piscataway, NJ 08854, USA.

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TOTomasz Osmałek
Tomasz Osmałek
AFAnna Froelich
Anna Froelich
Barbara JadachBarbara Jadach
Barbara Jadach
ATAdam Tatarek
Adam Tatarek
PGPiotr Gadziński
Piotr Gadziński
Bozena Michniak-KohnBozena Michniak-Kohn
Bozena Michniak-Kohn
The vagina has been considered a potential drug administration route for centuries. Most of the currently marketed and investigated vaginal formulations are composed with the use of natural or synthetic polymers having different functions in the product. The vaginal route is usually investigated as an administration site for topically acting active ingredients; however, the anatomical and physiological features of the vagina make it suitable also for drug systemic absorption. In this review, the most important natural and synthetic polymers used in vaginal products are summarized and described, with special attention paid to the properties important in terms of vaginal application. Moreover, the current knowledge on the commonly applied and innovative dosage forms designed for vaginal administration was presented. The aim of this work was to highlight the most recent research directions and indicate challenges related to vaginal drug administrations. As revealed in the literature overview, intravaginal products still gain enormous scientific attention, and novel polymers and formulations are still explored. However, there are research areas that require more extensive studies in order to provide the safety of novel vaginal products.

2 February 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AFAnna Froelich
Anna Froelich
TOTomasz Osmałek
Tomasz Osmałek
Barbara JadachBarbara Jadach
Barbara Jadach
Vinam PuriVinam Puri
Vinam Puri
Bozena Michniak-KohnBozena Michniak-Kohn
Bozena Michniak-Kohn
Nose-to-brain drug delivery has recently attracted enormous attention as an alternative to other delivery routes, including the most popular oral one. Due to the unique anatomical features of the nasal cavity, drugs administered intranasally can be delivered directly to the central nervous system. The most important advantage of this approach is the ability to avoid the blood–brain barrier surrounding the brain and blocking the entry of exogenous substances to the central nervous system. Moreover, selective brain targeting could possibly avoid peripheral side effects of pharmacotherapy. The challenges associated with nose-to-brain drug delivery are mostly due to the small volume of the nasal cavity and insufficient drug absorption from nasal mucosa. These issues could be minimized by using a properly designed drug carrier. Microemulsions as potential drug delivery systems offer good solubilizing properties and the ability to enhance drug permeation through biological membranes. The aim of this review is to summarize the current status of the research focused on microemulsion-based systems for nose-to-brain delivery with special attention to the most extensively investigated neurological and psychiatric conditions, such as neurodegenerative diseases, epilepsy, and schizophrenia.

1 January 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
TRTannaz Ramezanli
Tannaz Ramezanli
BKBrian E. Kilfoyle
Brian E. Kilfoyle
ZZZheng Zhang
Zheng Zhang
Bozena Michniak-KohnBozena Michniak-Kohn
Bozena Michniak-Kohn

9 March 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PSParinbhai Shah
Parinbhai Shah
Benjamin GoodyearBenjamin Goodyear
Benjamin Goodyear
AHAnika Haq
Anika Haq
Vinam PuriVinam Puri
Vinam Puri
Bozena Michniak-KohnBozena Michniak-Kohn
Bozena Michniak-Kohn
Topical corticosteroids are used to treat a variety of skin conditions such as allergic reactions, eczema, and psoriasis. Niosomes are a novel surfactant-based delivery system that may be used to deliver desoximetasone via topical product application in order to mitigate common side effects associated with traditional oral delivery routes. The aim of this research was to identify the critical material attributes (CMAs) and critical process parameters (CPPs) that impact key characteristics of drug-loaded niosomes using a systematic quality by design (QbD) approach. An organic phase injection method was developed and used to manufacture the niosomes. The CMAs were identified to be drug amount, concentrations of surfactant and cholesterol, and types of lipids. The CPPs were phase volumes, temperature, mixing parameters, and addition rate based on previous research. The quality attributes measured were entrapment efficiency, particle size distribution, PDI, and zeta potential. These were used to determine the quality target product profile (QTPP) of niosomes. The experimental data indicate that the critical impacting variables for niosomes are: surfactant and cholesterol concentrations, mixing parameters, and organic-phase addition rate. Based on the experimental results of this study methanol:diethyl ether (75:25) as the organic system, drug:surfactant:cholesterol in 1:2:1 concentration, stearic acid as the charge-inducing material, 20 mL external phase and 10 mL internal phase volume, 65 °C external phase temperature, 60 min mixing time, 650 RPM mixing speed and 1 mL/ml addition rate is the ideal combination to achieve desirable desoximetasone niosomes with optimum entrapment efficiency and particle size for topical application.


Verified
Journal Article
Open access
PDF file
KWKatarzyna Witkowska
Katarzyna Witkowska
MPMagdalena Paczkowska-Walendowska
Magdalena Paczkowska-Walendowska
TPTomasz Plech
Tomasz Plech
DSDaria Szymanowska
Daria Szymanowska
Bozena Michniak-KohnBozena Michniak-Kohn
Bozena Michniak-Kohn
Judyta Cielecka-PiontekJudyta Cielecka-Piontek
Judyta Cielecka-Piontek
Centella asiatica extract is a valued plant material with known anti-inflammatory and anti-microbiological properties. Using the Design of Experiment (DoE) approach, it was possible to obtain an optimized water/alcoholic extract from Centella asiatica, which allowed the preparation of the final material with biological activity in the wound healing process. Studies on the novel applications of Centella asiatica in conjunction with the multifunctional chitosan carrier have been motivated by the plant’s substantial pharmacological activity and the need to develop new and effective methods for the treatment of chronic wounds. The controlled release of asiaticoside was made possible by the use of chitosan as a carrier. Based on the findings of investigations using the PAMPA skin assay, which is a model imitating the permeability of actives through skin, this compound, characterized by sustained release from the chitosan delivery system, was identified as being well able to permeate biological membranes such as skin. Chitosan and the lyophilized extract of Centella asiatica worked synergistically to block hyaluronidase, exert efficient microbiological activity and take part in the wound healing process, as proven in an in vitro model. A formulation containing 3% extract with 3% medium-molecular-weight chitosan was indicated as a potentially new treatment with high compliance and effectiveness for patients. Optimization of the chitosan-based hydrogel preparation ensured the required rheological properties necessary for the release of the bioactive from the chitosan delivery system and demonstrated a satisfactory antimicrobial activity.